Related Experiment Video
Updated: Jul 5, 2026
06:18
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Transdermal 17-beta estradiol replacement therapy reduces megakaryocyte GPVI expression
Hongquan Geng1, Hui Zhang, Wei Zhang
1Medicine/Thrombosis Research, Baylor College of Medicine, Houston, TX, USA.
Thrombosis Research
|May 2, 2008
Summary
Transdermal estradiol (E2) reduces platelet glycoprotein VI (GPVI) expression and function in mice. This effect appears indirect, mediated by E2
Area of Science:
- Cardiovascular Biology
- Endocrinology
- Hematology
Background:
- Platelet-collagen interaction is crucial for arterial thrombus formation.
- Platelet glycoprotein VI (GPVI) is the primary collagen receptor.
- Estrogen's effects on platelets vary with formulation and administration route.
Purpose of the Study:
- To investigate the inhibitory effects of transdermal estradiol (E2) on platelet GPVI.
- To explore the mechanism behind E2's influence on GPVI-mediated platelet activation.
Main Methods:
- Utilized a mouse model of transdermal estradiol (E2) administration in ovariectomized mice.
- Assessed platelet GPVI expression, shedding, and function (fibrinogen binding, aggregation).
- Examined GPVI expression in bone marrow megakaryocytes.
Main Results:
- Transdermal E2 replacement therapy significantly reduced platelet GPVI expression.
- No direct shedding of GPVI was observed when platelets were incubated with E2.
- Reduced GPVI-mediated platelet aggregation and fibrinogen binding occurred after 9+ days of E2 treatment.
- E2 replacement decreased megakaryocyte GPVI expression in mouse bone marrow.
Conclusions:
- Transdermal estradiol (E2) indirectly inhibits platelet GPVI expression and function.
- E2 appears to act centrally on megakaryocytes to regulate GPVI levels in platelets.
- This suggests a novel mechanism for estrogen's modulation of platelet activity.
Related Concept Videos
01:18Transdermal Drug Delivery Systems
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...